Research Collaboration and Sub-licensing Agreements (Details) € in Thousands					3 Months Ended		6 Months Ended
	Jun. 24, 2020	May 07, 2019 protein antibody_and_vaccine	Jun. 30, 2017 USD ($)	Jun. 30, 2017 EUR (€)	Jun. 30, 2020 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2019 USD ($)	Dec. 31, 2019 USD ($)	Apr. 26, 2019	Mar. 31, 2018 USD ($)	Jun. 30, 2017 EUR (€)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Duration of agreement			2 years	2 years
Payment for research and development agreement			$ 1,100,000	€ 1,000
Prepaid expenses and other current assets					$ 16,261		$ 16,261		$ 0
Research and development - related party					0	$ 336,310	0	$ 725,783
Revenue from collaborative arrangement, recognized					$ 99,260		$ 174,632
Collaborative Arrangement | Serum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Number of antibodies and vaccines for development and commercialization | antibody_and_vaccine		12
Option to obtain exclusive commercial sub-license for number of proteins | protein		12
Research funding, milestone payments and royalties, period		15 years
Novovet
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Equity percentage										20.00%
Alphazyme
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Percentage of ownership after transaction	2.50%
RSA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment for research and development agreement | €				€ 1,000
Payment for additional development and commercialization | €												€ 1,500
RSA | Minimum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue sharing, percentage			50.00%	50.00%
RSA | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue sharing, percentage			75.00%	75.00%
RSA | BDI Holdings
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Equity interest acquired			16.10%	16.10%
RSA | VLPbio
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Equity interest acquired			3.30%	3.30%
RSA | BDI
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Duration of agreement			2 years	2 years
Obligation for payment for research and development, minimum | €												936
Obligation for payment for research and development, maximum | €												€ 8,000
RSA | BDI | Minimum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue sharing, percentage			50.00%	50.00%
RSA | BDI | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue sharing, percentage			75.00%	75.00%
SFA
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Duration of agreement			2 years	2 years
Obligation for payment for research and development, minimum			$ 1,000,000
Outstanding commitment											$ 1,000,000